Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

letsdodiz Jun. 26 at 5:27 PM

$BCTX trading at 1x cash which they confirmed they have $25M yesterday to see them through interim readout. Ground breaking ph3 therapy at $0 IP value.

0 · Reply

BHWinehouse Jun. 26 at 4:40 PM

$BCTX $BCTXL I can camp out here for months. Fully funded Pivotal Phase 3 trial Repeated positive safety reviews Promising efficacy signals Expanding immunotherapy pipeline FDA Fast Track designation US $2-5BILLION for just the first indication, up to $20B or more for multiple.

1 · Reply

jpurr Jun. 26 at 2:52 PM

$BCTX

0 · Reply

letsdodiz Jun. 25 at 7:32 PM

$BCTX from the roadshow it seems like we are looking at later in the year for the results . They confirmed the recent raise was to see them through the readout. They seemed too cautious about saying something that will pump up the price 😅.

1 · Reply

BHWinehouse Jun. 25 at 6:25 PM

$BCTX Funded through Q1 2027

1 · Reply

ZacksResearch Jun. 25 at 5:52 PM

$BCTX just locked in a key commercialization partner — and it's already being used in Phase 3 🔥 BriaCell signed an MoU with Uneedle to support commercial-scale production of its proprietary microneedle technology for Bria-IMT, the company's lead Phase 3 candidate for metastatic breast cancer. 🚀 ✅ Uneedle's device is already being used in BriaCell's ongoing pivotal Phase 3 study ✅ Collaboration focuses on regulatory and commercial readiness ahead of potential approval See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38544&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38544

0 · Reply

SmallCapGrowth Jun. 25 at 5:37 PM

$BCTX BriaCell taps Uneedle for scalable microneedle delivery of Bria‑IMT — tech already in the Phase 3 study for advanced metastatic breast cancer. Could speed up and simplify intradermal dosing. Read more: https://wix.to/OjE9cdH #Biotech #CancerResearch #MedTech

0 · Reply

SmallCapGrowth Jun. 25 at 5:17 PM

$BCTX

0 · Reply

ColeCapInvests Jun. 25 at 4:46 PM

$BCTX I forgot to mention another wonderful smell of BO with this Save the Big Stocktwitties Immunotherapy Juggs-er-nuts! They are waiting for death events to occur which are delayed just like $SLS !! Plus she’s a Low Floater on top of saving her Stocktitties! #Suckem Cancer

0 · Reply

SmallCapGrowth Jun. 25 at 4:42 PM

$BCTX taking steps beyond the clinic. Partnering with Uneedle - Xtremepicks Alerts https://investorshangout.com/post/view?id=6835321

0 · Reply

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T11:45:30.000Z - 1 day ago

BriaCell enters MoU with Uneedle for microneedle technology

Thu, 25 Jun 2026 07:30:00 -0400 - 1 day ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Tue, 02 Jun 2026 16:05:00 -0400 - 23 days ago

BriaCell Therapeutics Announces Closing of Offering

Mon, 01 Jun 2026 07:30:00 -0400 - 25 days ago

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 25 days ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 4 weeks ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 4 weeks ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 5 weeks ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 5 weeks ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 6 weeks ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 6 weeks ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 6 weeks ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 7 weeks ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 2 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 2 months ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 2 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 2 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 3 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 3 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 3 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 3 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 3 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 4 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 4 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 4 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 4 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 4 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 4 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 5 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 5 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 5 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 5 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 5 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 5 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 5 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

Jan 13, 2026, 9:00 PM EST - 5 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T14:41:11.000Z - 5 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 5 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T12:35:49.000Z - 5 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Jan 13, 2026, 7:30 AM EST - 5 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 6 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T12:41:29.000Z - 7 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

Dec 10, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T12:35:35.000Z - 7 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

Dec 9, 2025, 7:30 AM EST - 7 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:36:29.000Z - 7 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

Dec 2, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 7 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 7 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 7 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 8 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 8 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 21, 2025, 7:50 AM EDT - 8 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 8 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 10 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 11 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 11 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 11 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

letsdodiz Jun. 26 at 5:27 PM

$BCTX trading at 1x cash which they confirmed they have $25M yesterday to see them through interim readout. Ground breaking ph3 therapy at $0 IP value.

0 · Reply

BHWinehouse Jun. 26 at 4:40 PM

1 · Reply

jpurr Jun. 26 at 2:52 PM

$BCTX

0 · Reply

letsdodiz Jun. 25 at 7:32 PM

1 · Reply

BHWinehouse Jun. 25 at 6:25 PM

$BCTX Funded through Q1 2027

1 · Reply

ZacksResearch Jun. 25 at 5:52 PM

0 · Reply

SmallCapGrowth Jun. 25 at 5:37 PM

0 · Reply

SmallCapGrowth Jun. 25 at 5:17 PM

$BCTX

0 · Reply

ColeCapInvests Jun. 25 at 4:46 PM

0 · Reply

SmallCapGrowth Jun. 25 at 4:42 PM

$BCTX taking steps beyond the clinic. Partnering with Uneedle - Xtremepicks Alerts https://investorshangout.com/post/view?id=6835321

0 · Reply

SmallCapGrowth Jun. 25 at 4:20 PM

BLUE SKY BREAKOUT : $BCTX BriaCell partners with Uneedle to... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177733904 via @Investors_Hub

0 · Reply

SmallCapGrowth Jun. 25 at 3:52 PM

$BCTX BriaCell partners with Uneedle to scale microneedle delivery of Bria‑IMT — supporting faster, more convenient intradermal dosing in its Phase 3 study. Details: https://wix.to/UEVYQWI #Biotech #ClinicalTrials #BriaCell

0 · Reply

SmallCapGrowth Jun. 25 at 3:48 PM

0 · Reply

SmallCapGrowth Jun. 25 at 3:35 PM

MOMO'S BREAKOUT BOARD : $BCTX taking steps beyond the clinic.... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177733661 via @Investors_Hub

0 · Reply

SmallCapGrowth Jun. 25 at 3:00 PM

$BCTX taking steps beyond the clinic. Partnering with Uneedle to scale proprietary microneedle tech used in its Phase 3 trial. Faster, more convenient dosing and improved patient experience. Commercial strategy starting to take shape. NEWS: https://bit.ly/4v2fzJ3

0 · Reply

SmallCapGrowth Jun. 25 at 2:48 PM

New partnership for $BCTX 👇 BriaCell signs MoU with Uneedle to support commercial-scale microneedle delivery of Bria-IMT (Phase 3 breast cancer). Keys to watch: • Regulatory path • Manufacturing scale-up • Patient-friendly delivery edge NEWS: https://bit.ly/4v2fzJ3

0 · Reply

SmallCapGrowth Jun. 25 at 2:46 PM

BriaCell Therapeutics Corp ( $BCTX ): $BCTX partnered with Uneedle to scale mi... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177733550 via @Investors_Hub @smallcapvoice

0 · Reply

SmallCapGrowth Jun. 25 at 2:44 PM

$BCTX BriaCell partners with Uneedle to scale microneedle delivery of Bria-IMT — aiming for faster, more convenient intradermal administration as used in the Phase 3 study. Full story: https://wix.to/6WXUKDd #Biotech #Oncology #MedTech

0 · Reply

BHWinehouse Jun. 25 at 2:27 PM

$BCTX Today @ 2:00 EST

0 · Reply

JediGreen Jun. 25 at 1:24 PM

$BCTX

0 · Reply

Kirubin Jun. 25 at 12:38 PM

$BCTX now this is worthy of news! Pathetic!

0 · Reply

RafaSantos Jun. 25 at 12:31 PM

$BCTX Excellent news https://feeds.issuerdirect.com/news-release.html?newsid=4583956826476124&symbol=BCTX

0 · Reply

Market Cap	26.36M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	75,219
Avg Vol	217,776
Day's Range	N/A - N/A
Shares Out	8.70M
Stochastic %K	62%
Beta	1.21
Analysts	Strong Buy
Price Target	$40.00